SELECTION OF HUMAN TNFa SPECIFIC ANTIBODIES

• Main Authors: SMITH, ERNEST, S, SCRIVENS, MARIA, G., M, CROY, LESLIE, A
• Format: Patent
• Language: English; French
• Published: 16.10.2008
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; DERIVATIVES THEREOF; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; NUCLEIC ACIDS; NUCLEOSIDES; NUCLEOTIDES; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; SUGARS; VINEGAR; WINE

The invention relates to antibodies which bind to tumor necrosis factor a (TNFa) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFa - mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFa to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention. L'invention concerne des anticorps qui se lient au facteur de nécrose tumorale a (TNFa) et ses utilisations, en particulier dans le diagnostic et le traitement de maladies auto-immunes, par exemple, l'arthrite rhumatoïde (AR). L'invention concerne également des anticorps monoclonaux humains spécifiques qui inhibent les voies de signalisation médiées par le TNFa, et des variantes, fragments et dérivés de ceux-ci. Elle concerne également des anticorps monoclonaux humains spécifiques qui inhibent la capacité du TNFa à se lier à son récepteur, ainsi que des fragments, variantes et dérivés de ces anticorps. L'invention concerne également des polynucléotides codant pour les anticorps ci-dessus ou des fragments, variantes ou dérivés de ceux-ci, ainsi que des vecteurs et des cellules hôtes comprenant ces polynucléotides. L'invention concerne en outre des procédés de diagnostic et de traitement de maladies auto-immunes, par exemple, l'arthrite rhumatoïde (AR), en utilisant des anticorps de l'invention.